Publications by authors named "T Oze"
Aim: Patients with chronic hepatitis B (CHB) remain at risk for hepatocellular carcinoma (HCC) even with nucleos(t)ide analog therapy. We evaluated risk factors for HCC development, including serum hepatitis B virus (HBV) RNA, hepatitis B core-related antigen level, and growth differentiation factor 15 (GDF15) level, a predictor of HCC development in patients with chronic hepatitis C.
Methods: We collected clinical data and stored serum from CHB patients without a history of HCC who were receiving nucleos(t)ide analog treatment for more than 1 year and whose HBV DNA level was less than 3.
Article Synopsis
- - This study evaluated the effectiveness and safety of atezolizumab plus bevacizumab in treating unresectable hepatocellular carcinoma in real-world settings, involving 222 patients from 19 hospitals.
- - The findings revealed an objective response rate of 22.0% and a median progression-free survival of 5.7 months, with certain factors (like younger age, more tumors, and macrovascular invasion) linked to shorter progression-free survival.
- - Despite a median overall survival not being reached, key risk factors for reduced survival included absence of hyperlipidemia, multiple intrahepatic tumors, macrovascular invasion, and elevated neutrophil-to-lymphocyte ratios, with 36.0% of
Aim: In patients with chronic hepatitis C, hepatocellular carcinoma (HCC) occurs at a certain frequency, even if a sustained virologic response (SVR) is achieved by antiviral treatment. Old age, liver fibrosis, and high post-treatment α-fetoprotein (AFP) level are typical risk factors of post-SVR HCC. We examined whether the frequencies and factors of HCC in patients with an SVR achieved from interferon treatment changed.
View Article and Find Full Text PDFArticle Synopsis
- Resistance-associated substitutions (RASs) in hepatitis C virus (HCV) arise when treatments with direct-acting antivirals (DAAs) fail, with significant variants identified in most patients who didn't respond to specific therapies.
- In a study of 11 HCV genotype 1b patients, major variants L31M/V-Y93H were often found after treatment, while minor forms appeared before therapy in some cases, suggesting they were pre-existing.
- The research indicated that new mutations can develop during treatment and that RASs can result from both the selection of existing variants in the virus population and the creation of entirely new mutations during antiviral therapy.
Aim: Simeprevir (SMV)-based triple therapy is an effective retreatment option following failure of telaprevir (TVR)-based triple therapy. However, it is unclear whether the persistence of resistance-associated variants (RAVs) induced by TVR-based therapy may reduce the treatment effect of SMV-based therapy.
Methods: The factors associated with the treatment effect, including RAVs in the NS3 region, were examined in 21 patients with genotype 1b HCV infection who were treated with SMV-based therapy after failure of TVR-based therapy.